Early prostate cancer (T1–2N0M0)

Michael Scott, Amber Orman, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The definitive treatment of early stage prostate cancer with radiation therapy has progressed dramatically over the past two decades primarily due to the development and implementation of intensity-modulated radiation therapy (IMRT) techniques and better definition of the role of androgen deprivation therapy (ADT). IMRT has permitted the escalation of radiotherapy dose to the target tissues, namely, the prostate and proximal seminal vesicles, in an effort to improve tumor cell killing and local tumor control, while also reducing dose to nearby organs at risk (OARs) including the bladder, rectum, bowel, femoral heads, and penile bulb. Advances in image-guided radiotherapy (IGRT) have improved the accuracy of the delivery of IMRT, reduced PTV margins, and consequently decreased acute and long-term side effects. This chapter will review the clinical evidence for the use of IMRT for early stage, clinically localized (T1–2N0M0) prostate cancer and will outline the processes involved in designing and implementing a safe and effective IMRT treatment plan.

Original languageEnglish (US)
Title of host publicationIntensity-Modulated Radiation Therapy: Clinical Evidence and Techniques
PublisherSpringer Japan
Pages355-378
Number of pages24
ISBN (Print)9784431554868, 9784431554851
DOIs
StatePublished - Jan 1 2015

Fingerprint

radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Image-Guided Radiotherapy
tumors
Organs at Risk
deprivation
Seminal Vesicles
rectum
dosage
bulbs
Thigh
bladder
Rectum
Androgens
Prostate
Neoplasms
organs
Urinary Bladder

Keywords

  • Androgen deprivation therapy
  • Image-guided treatment delivery
  • Interfraction motion
  • Intrafraction motion
  • Risk classifications

ASJC Scopus subject areas

  • Medicine(all)
  • Physics and Astronomy(all)

Cite this

Scott, M., Orman, A., & Pollack, A. (2015). Early prostate cancer (T1–2N0M0). In Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques (pp. 355-378). Springer Japan. https://doi.org/10.1007/978-4-431-55486-8_19

Early prostate cancer (T1–2N0M0). / Scott, Michael; Orman, Amber; Pollack, Alan.

Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques. Springer Japan, 2015. p. 355-378.

Research output: Chapter in Book/Report/Conference proceedingChapter

Scott, M, Orman, A & Pollack, A 2015, Early prostate cancer (T1–2N0M0). in Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques. Springer Japan, pp. 355-378. https://doi.org/10.1007/978-4-431-55486-8_19
Scott M, Orman A, Pollack A. Early prostate cancer (T1–2N0M0). In Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques. Springer Japan. 2015. p. 355-378 https://doi.org/10.1007/978-4-431-55486-8_19
Scott, Michael ; Orman, Amber ; Pollack, Alan. / Early prostate cancer (T1–2N0M0). Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques. Springer Japan, 2015. pp. 355-378
@inbook{3d87eda45e5a453493d849fbe344fbcc,
title = "Early prostate cancer (T1–2N0M0)",
abstract = "The definitive treatment of early stage prostate cancer with radiation therapy has progressed dramatically over the past two decades primarily due to the development and implementation of intensity-modulated radiation therapy (IMRT) techniques and better definition of the role of androgen deprivation therapy (ADT). IMRT has permitted the escalation of radiotherapy dose to the target tissues, namely, the prostate and proximal seminal vesicles, in an effort to improve tumor cell killing and local tumor control, while also reducing dose to nearby organs at risk (OARs) including the bladder, rectum, bowel, femoral heads, and penile bulb. Advances in image-guided radiotherapy (IGRT) have improved the accuracy of the delivery of IMRT, reduced PTV margins, and consequently decreased acute and long-term side effects. This chapter will review the clinical evidence for the use of IMRT for early stage, clinically localized (T1–2N0M0) prostate cancer and will outline the processes involved in designing and implementing a safe and effective IMRT treatment plan.",
keywords = "Androgen deprivation therapy, Image-guided treatment delivery, Interfraction motion, Intrafraction motion, Risk classifications",
author = "Michael Scott and Amber Orman and Alan Pollack",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55486-8_19",
language = "English (US)",
isbn = "9784431554868",
pages = "355--378",
booktitle = "Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Early prostate cancer (T1–2N0M0)

AU - Scott, Michael

AU - Orman, Amber

AU - Pollack, Alan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The definitive treatment of early stage prostate cancer with radiation therapy has progressed dramatically over the past two decades primarily due to the development and implementation of intensity-modulated radiation therapy (IMRT) techniques and better definition of the role of androgen deprivation therapy (ADT). IMRT has permitted the escalation of radiotherapy dose to the target tissues, namely, the prostate and proximal seminal vesicles, in an effort to improve tumor cell killing and local tumor control, while also reducing dose to nearby organs at risk (OARs) including the bladder, rectum, bowel, femoral heads, and penile bulb. Advances in image-guided radiotherapy (IGRT) have improved the accuracy of the delivery of IMRT, reduced PTV margins, and consequently decreased acute and long-term side effects. This chapter will review the clinical evidence for the use of IMRT for early stage, clinically localized (T1–2N0M0) prostate cancer and will outline the processes involved in designing and implementing a safe and effective IMRT treatment plan.

AB - The definitive treatment of early stage prostate cancer with radiation therapy has progressed dramatically over the past two decades primarily due to the development and implementation of intensity-modulated radiation therapy (IMRT) techniques and better definition of the role of androgen deprivation therapy (ADT). IMRT has permitted the escalation of radiotherapy dose to the target tissues, namely, the prostate and proximal seminal vesicles, in an effort to improve tumor cell killing and local tumor control, while also reducing dose to nearby organs at risk (OARs) including the bladder, rectum, bowel, femoral heads, and penile bulb. Advances in image-guided radiotherapy (IGRT) have improved the accuracy of the delivery of IMRT, reduced PTV margins, and consequently decreased acute and long-term side effects. This chapter will review the clinical evidence for the use of IMRT for early stage, clinically localized (T1–2N0M0) prostate cancer and will outline the processes involved in designing and implementing a safe and effective IMRT treatment plan.

KW - Androgen deprivation therapy

KW - Image-guided treatment delivery

KW - Interfraction motion

KW - Intrafraction motion

KW - Risk classifications

UR - http://www.scopus.com/inward/record.url?scp=84943227077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943227077&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55486-8_19

DO - 10.1007/978-4-431-55486-8_19

M3 - Chapter

SN - 9784431554868

SN - 9784431554851

SP - 355

EP - 378

BT - Intensity-Modulated Radiation Therapy: Clinical Evidence and Techniques

PB - Springer Japan

ER -